CORONA Remedies commercialises women's hormone manufacturing facility in Ahmedabad

June 30, 2026 | Tuesday | News

CORONA's integrated manufacturing platform supports multiple dosage forms

CORONA Remedies has announced the inauguration and commercialisation of its dedicated EU-GMP approved Hormone Manufacturing Facility at Bhayla, Ahmedabad. The facility marks a significant milestone in the company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.

As global attention towards women's healthcare continues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fertility care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceutical manufacturing has become more critical than ever (as per WHO factsheet on Infertility Nov. 2025).

Hormonal medicines are among the most complex pharmaceutical products to manufacture. Their high potency, sensitive formulations and stringent contamination control requirements demand dedicated facilities equipped with sophisticated technologies, specialised engineering systems and uncompromising regulatory standards.

CORONA's integrated manufacturing platform supports multiple dosage forms—including tablets, soft gel capsules, ointments and gels—within a single specialised manufacturing ecosystem, enabling the company to cater to a broad spectrum of women's healthcare therapies.

Spread across 1.0 lakh sq. ft; the facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. With the commissioning of this facility, CORONA's in-house hormone manufacturing capacity is expected to increase by nearly 20%.